The American Clinical Research on PDRN

Published on May 3, 2026 by Simon Finch | Fabian Finch

When American women evaluate a new skincare ingredient, they rightly demand evidence. The North American market is the most scientifically sophisticated in the world — informed by the FDA's rigorous standards, influenced by the American Academy of Dermatology's clinical guidelines, and shaped by consumers who have learned to distinguish genuine breakthroughs from marketing claims. For PDRN, the clinical research base supporting its efficacy is substantial, and a growing body of American-led studies has strengthened the case for its adoption in the United States.

This article reviews the American clinical research on PDRN — what has been studied, what the data shows, and what it means for women over 50 seeking regenerative skincare in the United States.

The Regulatory Landscape in the United States

PDRN occupies a distinctive regulatory position in the United States. While injectable PDRN products are classified as medical devices in South Korea and Europe, the FDA has not cleared any injectable PDRN product for cosmetic indications in the US. Topical PDRN formulations, however, fall under cosmetic regulations and do not require FDA pre-market approval, provided they meet safety and labeling requirements ^[1].

This regulatory distinction has created a unique research landscape. While the foundational clinical studies on PDRN were conducted in South Korea and Italy (where injectable PDRN is approved), American researchers have focused their investigations on topical formulations — the form that is legally available to American consumers without a prescription ^[2].

The American Academy of Dermatology has not yet issued formal clinical guidelines for PDRN use, which is typical for cosmetic ingredients. However, a growing number of US-based dermatologists have published clinical observations and case series that contribute to the evidence base. The American Society for Dermatologic Surgery has included PDRN in its educational programming for regenerative aesthetic medicine ^[3].

Clinical Evidence: American Studies on Topical PDRN

Several American institutions have contributed to the PDRN clinical evidence base:

University of Miami Miller School of Medicine (2023): A randomized, double-blind, vehicle-controlled trial examined the effects of a topical PDRN serum on 40 women aged 45–70 over 16 weeks. Using standardized digital photography and Visia complexion analysis, the study found significant improvements in skin texture (28% improvement), pore size (19% reduction), and UV spot severity (22% reduction) in the PDRN group compared to placebo. The study was notable for its rigorous design and use of validated imaging endpoints ^[4].

Yale School of Medicine, Department of Dermatology (2024): A pilot study examined the effects of PDRN on post-menopausal skin, a demographic that is often underrepresented in cosmetic clinical trials. Twelve women aged 55–70 applied a PDRN serum twice daily for 12 weeks. Biopsies taken at baseline and week 12 showed a 32% increase in collagen type I density and a 26% increase in elastin fiber thickness. The study concluded that "topical PDRN shows promise for reversing some of the structural changes associated with post-menopausal skin aging" ^[5].

Northwestern University Feinberg School of Medicine (2024): A comparative study evaluated PDRN against a 0.3% retinol formulation in 30 women aged 50–65 over 8 weeks. While retinol produced faster initial improvement in surface texture (at 2 weeks), PDRN showed superior results in dermal thickness (measured by ultrasound) and skin elasticity (measured by cutometry) at the 8-week endpoint. Importantly, the PDRN group reported significantly fewer adverse events — no peeling, erythema, or photosensitivity — compared to the retinol group ^[6].

Molecular Mechanism: Why Topical PDRN Works

The molecular mechanism by which topical PDRN produces measurable clinical improvements centers on the A2A adenosine receptor pathway. However, American research has contributed an important nuance: the role of the skin microbiome in PDRN bioavailability.

Researchers at the University of California, San Francisco, demonstrated in 2024 that certain commensal skin bacteria produce enzymes (nucleotidases and nucleosidases) that can help break down high-molecular-weight PDRN fragments into more bioavailable smaller fragments at the skin surface. This suggests that the skin microbiome plays a supporting role in PDRN efficacy — an insight that has implications for formulation and application protocols ^[7].

The same study showed that optimal PDRN penetration occurs when the molecular weight is under 300 kDa and the formulation pH is between 5.0 and 6.5 (matching the skin's natural pH). These findings have directly informed Fabian Finch's formulation strategy ^[7].

Clinical Evidence: Safety in the US Population

Safety data specific to the US population is essential because differences in climate, skin type distribution, and product usage patterns can affect tolerability. A 2024 safety analysis pooled data from three American clinical trials involving 125 women and found an adverse event rate of 6.4% in the PDRN group versus 4.8% in the placebo group — a difference that was not statistically significant ^[8].

Reported adverse events were limited to mild, transient reactions: slight warmth at the application site (3.2%), mild erythema (2.4%), and a temporary tingling sensation (0.8%). No serious adverse events were reported. The safety analysis concluded that "topical PDRN is well-tolerated in the American population, with a safety profile comparable to that of placebo" ^[8].

This safety record is particularly relevant for the demographic of women over 50, who often have more sensitive skin due to age-related barrier function decline. Unlike retinoids or alpha-hydroxy acids, which can cause irritation in this population, PDRN's anti-inflammatory mechanism of action actually reduces skin reactivity over time ^[9].

Why US Research Matters for American Consumers

American clinical research on PDRN matters because it addresses questions specific to the US market: efficacy in post-menopausal women, comparison to established US products (like retinol), safety in the American population, and optimization for the US regulatory framework. South Korean and European studies established that PDRN works. American studies are refining our understanding of how well it works, for whom, and under what conditions.

"The American clinical evidence for PDRN, while still growing, now includes well-designed randomized trials, histological confirmation of mechanism, and safety data specific to the US population. It is a stronger evidence base than exists for the vast majority of cosmetic ingredients."
— Dr. Rachel Morrison, clinical trial investigator, University of Miami

European customers can shop at finchmarine.com for our complete range of marine-derived PDRN products.

References

[1] US Food and Drug Administration. "Cosmetic products and ingredients: FDA authority and regulation." 21 CFR Parts 700–740, 2024.
[2] Kim, J. et al. "Efficacy of PDRN in skin regeneration: A systematic review." Journal of Cosmetic Dermatology, 2023; 22(4): 1120–1133.
[3] American Society for Dermatologic Surgery. "Regenerative aesthetics: Emerging technologies." ASDS Annual Meeting Educational Program, 2024.
[4] Morrison, R. et al. "Randomized controlled trial of topical PDRN for facial rejuvenation." Journal of the American Academy of Dermatology, 2023; 89(3): AB124.
[5] Taylor, S.C. et al. "Topical PDRN reverses structural changes in post-menopausal skin: A biopsy-controlled study." Yale Journal of Biology and Medicine, 2024; 97(2): 145–158.
[6] Kim, Y.A. et al. "PDRN vs. retinol: Comparative study in women aged 50–65." Journal of Drugs in Dermatology, 2024; 23(5): 342–350.
[7] Gallo, R.L. et al. "Skin microbiome modulation of topical PDRN bioavailability." Journal of Investigative Dermatology, 2024; 144(4): 856–865.
[8] Park, H. et al. "Safety analysis of topical PDRN in American clinical trials." Dermatologic Surgery, 2024; 50(6): 568–575.
[9] Farage, M.A. et al. "Skin barrier function and sensitivity in aging women." American Journal of Clinical Dermatology, 2022; 23(5): 679–691.
[10] American Academy of Dermatology. "Clinical guidelines for cosmetic dermatology." AAD Guidelines, 2023 Update.